Market Cap : 41.77 B | Enterprise Value : 43.49 B | PE Ratio : 14.77 | PB Ratio : 3.27 |
---|
BIIB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIIB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Biogen's EBITDA per Share for the three months ended in Sep. 2022 was $10.72. Its EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2022 was $28.65.
During the past 12 months, the average EBITDA per Share Growth Rate of Biogen was 43.10% per year. During the past 3 years, the average EBITDA per Share Growth Rate was -16.70% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -2.70% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 13.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.
The historical rank and industry rank for Biogen's EBITDA per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Biogen was 161.50% per year. The lowest was -30.20% per year. And the median was 22.65% per year.
Biogen's EBITDA for the three months ended in Sep. 2022 was $1,552 Mil.
During the past 12 months, the average EBITDA Growth Rate of Biogen was 38.30% per year. During the past 3 years, the average EBITDA Growth Rate was -25.10% per year. During the past 5 years, the average EBITDA Growth Rate was -10.30% per year. During the past 10 years, the average EBITDA Growth Rate was 8.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.
During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Biogen was 201.30% per year. The lowest was -40.20% per year. And the median was 23.95% per year.
The historical data trend for Biogen's EBITDA per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Biogen's EBITDA per Share for the fiscal year that ended in Dec. 2021 is calculated as
EBITDA per Share | (A: Dec. 2021 ) | ||
= | EBITDA | / | Shares Outstanding (Diluted Average) | = | 2880.1 | / | 149.600 |
= | 19.25 |
Biogen's EBITDA per Share for the quarter that ended in Sep. 2022 is calculated as
EBITDA per Share | (Q: Sep. 2022 ) | ||
= | EBITDA | / | Shares Outstanding (Diluted Average) | = | 1551.7 | / | 144.800 |
= | 10.72 |
EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $28.65
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.
While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.
The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.
EBITDA can be thought of as the cash a business generates that is available to:
Add more inventoryEBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.
A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.
Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.
Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.
EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.
Thank you for viewing the detailed overview of Biogen's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Murphy Nicole | officer: Head of Pharm Ops and Tech | BIOGEN INC. 225 BINNEY STREET CAMBRIDGE MA 02142 |
Izzar Rachid | officer: Head of Alzheimer's Disease | BIOGEN INC. 225 BINNEY STREET CAMBRIDGE MA 02142 |
Jones William D /ca/ | director | |
Freire Maria C | director | C/O ALEXANDRIA REAL ESTATE EQUITIES, INC 26 NORTH EUCLID AVENUE PASADENA CA 91101 |
Mcdonnell Michael R | officer: EVP, Chief Financial Officer | C/O IQVIA HOLDINGS INC. 83 WOOSTER HEIGHTS ROAD DANBURY CT 06810 |
Galdes Alphonse | officer: EVP Pharmaceutical Oper & Tech | BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
Hawkins William A | director | MEDTRONIC INC 710 MEDTRONIC PKWY, MS LC310 MINNEAPOLIS MN 55432-5604 |
Mantas Jesus B | director | BIOGEN INC. 225 BINNEY STREET CAMBRIDGE MA 02142 |
Kramer Robin | officer: VP, Chief Accounting Officer | 999 VANDERBILT BEACH ROAD 3RD FLOOR NAPLES FL 34109 |
Karp Daniel | officer: EVP, Corporate Development | 225 BINNEY STREET CAMBRIDGE MA 02142 |
Capello Jeffrey D | officer: EVP & Chief Financial Officer | BOSTON SCIENTIFIC CORPORATION ONE BOSTON SCIENTIFIC PLACE NATICK MA 01760 |
Guindo Chirfi | officer: EVP Glob. Mkt Acc & Cust Innov | C/O BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
Gregory Ginger | officer: EVP, Human Resources | C/O BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
Kress Jean-paul | officer: EVP Pres Int'l & Global Hd GTO | 215 FIRST STREET, SUITE 415 CAMBRIDGE MA 02142 |
Mckenzie Paul | officer: EVP Pharmaceutical Oper & Tech | BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
From GuruFocus
By GuruFocusNews 02-22-2022
By GuruFocusNews 04-04-2022
By GuruFocusNews 03-05-2022
By GuruFocusNews 02-23-2022
By GuruFocusNews 04-04-2022
By PRNewswire 03-04-2022
By GuruFocusNews 03-13-2022
Other Sources
By Zacks 2022-03-10
By Zacks 2022-03-30
By tipranks.com 2022-02-21
By tipranks.com 2022-03-21
By Zacks 2022-03-28
By Zacks 2022-02-23
By Zacks 2022-03-01
By Zacks 2022-02-09
By Zacks 2022-02-17
By Zacks 2022-03-21
By Zacks 2022-04-04
By Zacks 2022-04-04
By Zacks 2022-02-24
By Zacks 2022-02-08
By Zacks 2022-03-29